Skip to content

Search

Showing results for "early lung health"

WA researchers lead global centre to eliminate childhood asthma

An ambitious project that could stop children developing asthma is the centrepiece of a new world-class respiratory research centre launched in Perth.

Scalability and scaling-up strategy of a physical activity policy intervention in Australian childcare centres

There is an urgent need for scalable interventions to promote physical activity in early childhood. An early childhood education and care physical activity policy intervention with implementation support strategies (Play Active) has been proposed for scale-up in Australia. 

Regulatory role of IL10 genetic variations in determining allergen-induced TH2 cytokine responses in children

Interleukin-10 is a key immunomodulatory cytokine the principal function of which is to limit the magnitude of immune response.

Toll-like receptor 7 function is reduced in adolescents with asthma

Anti-viral innate immune responses may be impaired in asthma, although the mechanisms are not well understood.

Nanoparticles and Children's Lungs: Is there a need for caution?

Nanoparticle research is currently an area of considerable interest due to the potential applications both in industry and medicine.

Protection against neonatal respiratory viral infection via maternal treatment during pregnancy with the benign immune training agent OM-85

Incomplete maturation of immune regulatory functions at birth is antecedent to the heightened risk for severe respiratory infections during infancy. Our forerunner animal model studies demonstrated that maternal treatment with the microbial-derived immune training agent OM-85 during pregnancy promotes accelerated postnatal maturation of mechanisms that regulate inflammatory processes in the offspring airways.

Translational Immunology

Our team aims to better understand how the immune response to immune challenges, such as viral infections can influence the risk of developing asthma or autoimmune disease.

Lack of effectiveness of 13-valent pneumococcal conjugate vaccination against pneumococcal carriage density in Papua New Guinean infants

Papua New Guinea (PNG) introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in 2014, with administration at 1, 2, and 3 months of age. PCV13 has reduced or eliminated carriage of vaccine types in populations with low pneumococcal carriage prevalence, carriage density and serotype diversity.

Infection and the development of allergic disease

An improved understanding of the roles of protein kinases in intracellular signalling and disease progression has driven significant advances in protein...